早期预测多黏菌素相关急性肾损伤的新型生物标志物研究进展

杨戈; 杨君; 刘芳; 陈勇川; 张洪

doi:10.6039/j.issn.1001-0408.2025.02.20

您当前的位置：

首页 >

文章列表页 >

早期预测多黏菌素相关急性肾损伤的新型生物标志物研究进展

综述 | 更新时间：2025-02-05

- 早期预测多黏菌素相关急性肾损伤的新型生物标志物研究进展
- Study progress of novel biomarkers for early prediction of polymyxin-associated acute kidney injury
- 中国药房 2025年36卷第2期页码：251-256
- 作者机构：
  
  1.武汉大学人民医院药剂科，武汉　430060
  2.陆军军医大学第一附属医院药剂科，重庆　400038
  3.陆军军医大学大坪医院药剂科，重庆　400042
- 作者简介：
  
  硕士研究生。研究方向：抗菌药物的临床应用、临床药理学。E-mail：ge_yang@126.com
  主任药师，硕士生导师。研究方向：靶向制剂、药物作用机制、抗肿瘤药物新剂型及基因个体化给药。电话：027-88041911-81794。E-mail：rm002397@whu.edu.cn
- 基金信息：
  
  重庆市科卫联合医学科研项目重点项目(2019ZDXM052);重庆市临床药学重点专科建设项目(渝卫办发〔2021〕52号);陆军军医大学苗圃人才库项目(XZ-2019-505-073)
- DOI：10.6039/j.issn.1001-0408.2025.02.20
  中图分类号： R978.1+6;R692
- 纸质出版日期：2025-01-30，
  
  收稿日期：2024-07-30，
  
  修回日期：2024-12-26，
  
  录用日期：2024-12-27
- 稿件说明：
移动端阅览
杨戈,杨君,刘芳等.早期预测多黏菌素相关急性肾损伤的新型生物标志物研究进展 [J].中国药房,2025,36(02):251-256.

YANG Ge,YANG Jun,LIU Fang,et al.Study progress of novel biomarkers for early prediction of polymyxin-associated acute kidney injury[J].ZHONGGUO YAOFANG,2025,36(02):251-256.
杨戈,杨君,刘芳等.早期预测多黏菌素相关急性肾损伤的新型生物标志物研究进展 [J].中国药房,2025,36(02):251-256. DOI： 10.6039/j.issn.1001-0408.2025.02.20.

YANG Ge,YANG Jun,LIU Fang,et al.Study progress of novel biomarkers for early prediction of polymyxin-associated acute kidney injury[J].ZHONGGUO YAOFANG,2025,36(02):251-256. DOI： 10.6039/j.issn.1001-0408.2025.02.20.

摘要

多黏菌素是治疗多重耐药革兰氏阴性菌感染的关键药物，但其显著的肾毒性严重限制了临床应用。为提升其安全性并改善患者预后，探索早期预测多黏菌素相关急性肾损伤的新型生物标志物尤为重要。胱抑素C、肾损伤分子1、中性粒细胞明胶酶相关脂质运载蛋白、

-乙酰-

-葡萄糖苷酶、β2微球蛋白等新型生物标志物在多黏菌素相关急性肾损伤早期预测中表现出了明显的优势。相较于传统标志物，这些标志物可在肾损伤的早期阶段提供敏感、特异的诊断信息，有助于优化个体治疗方案，降低临床风险。然而，检测成本较高、操作复杂等问题仍限制了上述标志物的临床推广。未来的研究应重点优化新型生

物标志物的检测技术，简化操作流程并降低成本，同时开展多中心、大样本的随机对照试验，系统评估各种新型生物标志物的敏感性和特异性，以推动其在临床肾损伤预测领域中的应用。

Abstract

Polymyxin is an essential antibiotic for treating multidrug-resistant Gram-negative bacterial infections； however， its significant nephrotoxicity greatly limits its clinical application. To enhance its safety and improve patient outcomes， the study of novel biomarkers for the early prediction of polymyxin-associated acute kidney injury is critically important. Novel biomarkers， such as cystatin C， kidney injury molecule-1， neutrophil gelatinase-associated lipocalin，

-acetyl-

-glucosaminidase， β2-microglobulin， have shown obvious advantages in the early prediction of polymyxin-associated acute kidney injury. Compared to traditional biomarkers， these biomarkers can provide sensitive and specific diagnostic information in the early stages of kidney injury， helping to optimize individualized treatment plans and reduce clinical risks. However， the high cost of detection and complex operation still limit their clinical promotion. Future research should focus on optimizing the detection technology of new biomarkers， simplifying the operation process and reducing costs， while conducting multi-center， large-scale randomized controlled trials to systematically evaluate the sensitivity and specificity of various novel biomarkers， in order to promote their application in the field of prediction of renal injury in clinical practice.

关键词

新型生物标志物多黏菌素急性肾损伤肾毒性早期预测

Keywords

polymyxinacute kidney injurynephrotoxicityearly prediction

references

HOU J，LONG X，WANG X L，et al. Global trend of antimicrobial resistance in common bacterial pathogens in response to antibiotic consumption[J]. J Hazard Mater，2023，442：130042.

ARDEBILI A，IZANLOO A，RASTEGAR M. Polymyxin combination therapy for multidrug-resistant，extensively-drug resistant，and difficult-to-treat drug-resistant Gram-negative infections：is it superior to polymyxin monotherapy?[J]. Expert Rev Anti Infect Ther，2023，21（4）：387-429.

NANG S C，AZAD M A K，VELKOV T，et al. Rescuing the last-line polymyxins：achievements and challenges[J]. Pharmacol Rev，2021，73（2）：679-728.

陈丽娟，吴晓丽，杨康群，等. 多黏菌素B对多重耐药革兰阴性细菌感染的疗效与肾毒性分析[J]. 中华全科医师杂志，2021，20（9）：997-1002.

CHEN L J，WU X L，YANG K Q，et al. Therapeutic effect and nephrotoxicity of polymyxin B on multidrug-resistant Gram-negative bacteria infection[J]. Chin J Gen Pract，2021，20（9）：997-1002.

GAI Z B，SAMODELOV S L，KULLAK-UBLICK G A，et al. Molecular mechanisms of colistin-induced nephrotoxicity[J]. Molecules，2019，24（3）：653.

SALES G T M，FORESTO R D. Drug-induced nephroto-xicity[J]. Rev Assoc Med Bras（1992），2020，66（Suppl. 1）：s82-s90.

PYE K，TASINATO E，SHUTTLEWORTH S，et al. Comparison of the impact of VRP-034 and polymyxin B upon markers of kidney injury in human proximal tubule monolayers in vitro[J]. Antibiotics，2024，13（6）：530.

SHAFIK M S，EL-TANBOULY D M，BISHR A，et al. Insights into the role of PHLPP2/Akt/GSK3β/Fyn kinase/Nrf2 trajectory in the Reno-protective effect of rosu-vastatin against colistin-induced acute kidney injury in rats[J]. J Pharm Pharmacol，2023，75（8）：1076-1085.

NARAKI K，GHASEMZADEH RAHBARDAR M，RAZAVI B M，et al. The power of trans-sodium crocetinate：exploring its renoprotective effects in a rat model of colistin-induced nephrotoxicity[J]. Naunyn Schmiedebergs Arch Pharmacol，2024，397（12）：10155-10174.

JIANG X K，ZHANG S，AZAD M A K，et al. Structure-interaction relationship of polymyxins with the membrane of human kidney proximal tubular cells[J]. ACS Infect Dis，2020，6（8）：2110-2119.

YOON S Y，KIM J S，JEONG K H，et al. Acute kidney injury：biomarker-guided diagnosis and management[J]. Medicina（Kaunas），2022，58（3）：340.

MCKENNA Z J，ATKINS W C，FOSTER J，et al. Kidney function biomarkers during extreme heat exposure in young and older adults[J]. JAMA，2024，332（4）：333-335.

XIN Y，LIU Y Q，LIU L Q，et al. Dynamic changes in the real-time glomerular filtration rate and kidney injury mar-kers in different acute kidney injury models[J]. J Transl Med，2024，22（1）：857.

LARKI R A，JAMALI B，MEIDANI M，et al. Serum cysta-tin C for evaluation of acute kidney injury in adults treated with colistin[J]. J Res Pharm Pract，2018，7（4）：178-181.

ORDOOEI JAVAN A，SHOKOUHI S，SAHRAEI Z，et al. Nephrotoxicity of high and conventional dosing regimens of colistin：a randomized clinical trial[J]. Iran J Pharm Res，2017，16（2）：781-790.

TAJIMA S，YAMAMOTO N，MASUDA S. Clinical pro-spects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy[J]. Biochem Pharmacol，2019，170：113664.

LEVEY A S，INKER L A，CORESH J. GFR estimation：from physiology to public health[J]. Am J Kidney Dis，2014，63（5）：820-834.

WAINBERG M，KLOIBER S，DINIZ B，et al. Clinical laboratory tests and five-year incidence of major depressive disorder：a prospective cohort study of 433 890 participants from the UK Biobank[J]. Transl Psychiatry，2021，11（1）：380.

GENG J W，QIU Y X，QIN Z，et al. The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients：a systematic review and Bayesian meta-analysis[J]. J Transl Med，2021，19（1）：105.

NIESKENS T T G，SJÖGREN A K. Emerging in vitro systems to screen and predict drug-induced kidney toxicity[J]. Semin Nephrol，2019，39（2）：215-226.

LIU L Q，LIU Y X，XIN Y，et al. An early and stable mouse model of polymyxin-induced acute kidney injury[J]. Intensive Care Med Exp，2024，12（1）：88.

BABIC J T，MANCHANDANI P，LEDESMA K R，et al. Evaluation of urinary KIM-1 for prediction of polymyxin B-induced nephrotoxicity[J]. Antimicrob Agents Chemother，2017，61（11）：e01735-17.

KIM K，LEE A，RYU J Y，et al. Application of microflui-dic perfusion culture for assessment of colistin nephroto-xicity[J]. Rom Biotechnol Lett，2020，25（4）：1724-1730.

ROMEJKO K，MARKOWSKA M，NIEMCZYK S. The review of current knowledge on neutrophil gelatinase-associated lipocalin（NGAL）[J]. Int J Mol Sci，2023，24（13）：10470.

SISTI G，RUBIN G，ZHOU C，et al. Neutrophil gelatinase-associated lipocalin as a predictor of pre-eclampsia：a systematic review and meta-analysis[J]. Int J Gynaecol Obstet，2023，163（1）：63-74.

DA Y，AKALYA K，MURALI T，et al. Serial quantification of urinary protein biomarkers to predict drug-induced acute kidney injury[J]. Curr Drug Metab，2019，20（8）：656-664.

ORDOOEI JAVAN A，SALAMZADEH J，SHOKOUHI S，et al. Evaluation of renal toxicity of colistin therapy with neutrophil gelatinase-associated lipocalin：a biomarker of renal tubular damage[J]. Iran J Kidney Dis，2017，11（6）：447-455.

SHAVIT L，MANILOV R，WIENER-WELL Y，et al. Urinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistin[J]. Clin Nephrol，2013，80（6）：405-416.

LATOCH E，KONOŃCZUK K，MUSZYŃSKA-ROSŁAN K，et al. Urine NGAL and KIM-1-tubular injury biomarkers in long-term survivors of childhood solid tumors：a cross-sectional study[J]. J Clin Med，2021，10（3）：399.

PETROVA I，ALEXANDROV A，VLADIMIROV G，et al. NGAL as biomarker of clinical and subclinical damage of kidney function after coronary angiography[J]. Diagnostics，2023，13（6）：1180.

KIM H K，LEE M，LEE Y H，et al. Renal tubular damage marker，urinary N-acetyl-β-D-glucosaminidase，as a predictive marker of hepatic fibrosis in type 2 diabetes mel-litus[J]. Diabetes Metab J，2022，46（1）：104-116.

YAN F，TIAN X G，LUAN Z L，et al. NAG-targeting fluorescence based probe for precision diagnosis of kidney injury[J]. Chem Commun（Camb），2019，55（13）：1955-1958.

ETHERINGTON C，BOSOMWORTH M，CLIFTON I，et al. Measurement of urinary N-acetyl-β-D-glucosaminidase in adult patients with cystic fibrosis：before，during and after treatment with intravenous antibiotics[J]. J Cyst Fibros，2007，6（1）：67-73.

SUZUKI T，YAMAGUCHI H，OGURA J，et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin[J]. Antimicrob Agents Chemother，2013，57（12）：6319-6324.

张潇伊，蒯铮，邹云增. β2-微球蛋白的研究进展[J]. 中国临床药理学与治疗学，2022，27（4）：390-396.

ZHANG X Y，KUAI Z，ZOU Y Z. Research progress of β2 microglobulin[J]. Chin J Clin Pharmacol Ther，2022，27（4）：390-396.

LIU Z Y，TANG F，WANG J，et al. Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients：a preliminary clinical study[J]. BMC Cancer，2024，24（1）：692.

LOCCI E，LIU J J，PAIS G M，et al. Urinary metabolomics from a dose-fractionated polymyxin B rat model of acute kidney injury[J]. Int J Antimicrob Agents，2022，60（1）：106593.

KEIRSTEAD N D，WAGONER M P，BENTLEY P，et al. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers[J]. Toxicol Sci，2014，137（2）：278-291.

HART A，CESAR F，ZELNICK L R，et al. Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosis[J]. J Cyst Fibros，2024，23（2）：293-299.

ZHOU Z Z，ZHANG D L，WANG Y J，et al. Urinary exosomes：a promising biomarker of drug-induced nephroto-xicity[J]. Front Med，2023，10：1251839.

BAZARGANI B，MOGHTADERI M. New biomarkers in early diagnosis of acute kidney injury in children[J]. Avicenna J Med Biotechnol，2022，14（4）：264-269.

KAMIANOWSKA M，RYBI-SZUMIŃSKA A，KAMIANOWSKA A，et al. Urinary concentration of renal biomarkers in healthy term neonates：gender differences in GST-pi excretion[J]. Med Sci Monit，2024，30：e942819.

KATOU，GLOBKE B，MORGUL M H，et al. Urinary biomarkers α-GST and π-GST for evaluation and monitoring in living and deceased donor kidney grafts[J]. J Clin Med，2019，8（11）：1899.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据